Skip to main content

Advertisement

SpringerLink
Log in

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate.

Patients and methods

We conducted a multicentre phase II trial assessing the disease control rate (DCR) of the combination of tegafur/uracil and mitomycin C in rmCRC. The number of previous lines of chemotherapy, carcinoembryonic antigen (CEA) levels, progression-free survival of the last chemotherapy regimen (PPFS), and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio at the time of study entry were evaluated as indicators of early progression.

Results

We enrolled 42 patients. The combination was well tolerated with a DCR of 26.2% and median overall survival of 6.9 months. Low CEA levels, PPFS >6 months and low NLR were significantly associated with better prognosis.

Conclusion

The study failed its primary endpoint. However, some putative indicators of early progressive patients have been described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

    Article  PubMed  Google Scholar 

  2. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30

    Article  CAS  PubMed  Google Scholar 

  3. Hoff PM, Pazdur R, Benner SE, Canetta R (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer 9(6):479–490

    CAS  Google Scholar 

  4. Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Clin Oncol 20(17):3605–3616

    Article  CAS  Google Scholar 

  5. Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20(17):3617–3627

    Article  CAS  PubMed  Google Scholar 

  6. Paz MM, Zhang X, Lu J, Holmgren A (2012) A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol 25(7):1502–1511

    Article  CAS  PubMed  Google Scholar 

  7. Verweij J, Pinedo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1(1):5–13

    Article  CAS  PubMed  Google Scholar 

  8. Ferrarotto R, Machado K, Mak MP et al (2012) A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820–826

    Article  CAS  PubMed  Google Scholar 

  9. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

    Article  CAS  PubMed  Google Scholar 

  10. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed Aug 2006

  11. Galizia G, Lieto E, Zamboli A et al (2015) Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. Surgery 158(1):112–120

    Article  PubMed  Google Scholar 

  12. Absenger G, Szkandera J, Pichler M et al (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2):395–400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Neofytou K, Smyth EC, Giakoustidis A et al (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 31(10):239

    Article  PubMed  Google Scholar 

  14. Kodaira S (1997) Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer. Oncology (Williston Park) 11(9 Suppl 10):40–43

    CAS  Google Scholar 

  15. Nakagoe T, Ishikawa H, Sawai T et al (2000) Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer. Anticancer Res 20(2B):1069–1075

    CAS  PubMed  Google Scholar 

  16. Gyldenkerne N, Glimelius B, Frödin JE et al (2004) A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol 43(3):276–279

    Article  CAS  PubMed  Google Scholar 

  17. Vormittag L, Kornek GV, Gruhsmann B et al (2007) UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer − a retrospective analysis. Anticancer Drugs 18(6):709–712

    Article  CAS  PubMed  Google Scholar 

  18. Alkis N, Demirci U, Benekli M et al (2011) Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 16(1):80–83

    CAS  PubMed  Google Scholar 

  19. Francois E, Smith D, Dahan L et al (2012) Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. J Chemother 24(4):207–211

    Article  CAS  PubMed  Google Scholar 

  20. Michalaki V, Gennatas S, Gennatas C (2010) Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON 15(2):270–273

    CAS  PubMed  Google Scholar 

  21. Grothey A, Van Cutsem E, Sobrero A et al (2013) CORRECT Study Group: regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312

    Article  CAS  PubMed  Google Scholar 

  22. Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919

    Article  PubMed  Google Scholar 

  23. Tampellini M, Ottone A, Alabiso I et al (2015) The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy. Tumour Biol 36(3):1519–1527

    Article  CAS  PubMed  Google Scholar 

  24. Li MX, Liu XM, Zhang XF et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10):2403–2413

    Article  CAS  PubMed  Google Scholar 

  25. Del Prete M, Giampieri R, Loupakis F et al (2015) Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 6(32):33982–33992

    PubMed  PubMed Central  Google Scholar 

  26. Petrelli F, Coinu A, Cabiddu M et al (2015) Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. Med Oncol 32(2):456

    Article  PubMed  Google Scholar 

  27. Giessen C, Laubender RP, Ankerst DP et al (2015) Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials. Acta Oncol 54:187–193

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Oncology, AOU San Luigi di Orbassano, University of Torino, Regione Gonzole 10, Orbassano, 10043, Turin, Italy

    Chiara Baratelli, Marco Tampellini, Massimo Di Maio, Azzurra Ottone, Maria Pia Brizzi, Laura Forti, Irene Alabiso, Cristina Sonetto, Oscar Alabiso & Giorgio Vittorio Scagliotti

Authors
  1. Chiara Baratelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Tampellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimo Di Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Azzurra Ottone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Pia Brizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laura Forti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Irene Alabiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cristina Sonetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Oscar Alabiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giorgio Vittorio Scagliotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Sonetto.

Ethics declarations

Conflict of interest

The authors declare no potential conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baratelli, C., Tampellini, M., Di Maio, M. et al. MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression. Int J Clin Oncol 23, 281–286 (2018). https://doi.org/10.1007/s10147-017-1195-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1195-x

Keywords

Search

Navigation